Cargando…

Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture

Translation of multipotent mesenchymal stromal cell (MSC)-based therapies is advancing in human and veterinary medicine. One critical issue is the in vitro culture of MSC before clinical use. Using fetal bovine serum (FBS) as supplement to the basal medium is still the gold standard for cultivation...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagen, A., Lehmann, H., Aurich, S., Bauer, N., Melzer, M., Moellerberndt, J., Patané, V., Schnabel, C. L., Burk, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859354/
https://www.ncbi.nlm.nih.gov/pubmed/33553119
http://dx.doi.org/10.3389/fbioe.2020.613621
_version_ 1783646713407340544
author Hagen, A.
Lehmann, H.
Aurich, S.
Bauer, N.
Melzer, M.
Moellerberndt, J.
Patané, V.
Schnabel, C. L.
Burk, J.
author_facet Hagen, A.
Lehmann, H.
Aurich, S.
Bauer, N.
Melzer, M.
Moellerberndt, J.
Patané, V.
Schnabel, C. L.
Burk, J.
author_sort Hagen, A.
collection PubMed
description Translation of multipotent mesenchymal stromal cell (MSC)-based therapies is advancing in human and veterinary medicine. One critical issue is the in vitro culture of MSC before clinical use. Using fetal bovine serum (FBS) as supplement to the basal medium is still the gold standard for cultivation of many cell types including equine MSC. Alternatives are being explored, with substantial success using platelet lysate-supplemented media for human MSC. However, progress lags behind in the veterinary field. The aim of this study was to establish a scalable protocol for equine platelet lysate (ePL) production and to test the ePL in equine MSC culture. Whole blood was harvested into blood collection bags from 20 healthy horses. After checking sample materials for pathogen contamination, samples from 19 animals were included. Platelet concentrates were prepared using a buffy coat method. Platelets, platelet-derived growth factor BB, and transforming growth factor β1 concentrations were increased in the concentrates compared with whole blood or serum (p < 0.05), while white blood cells were reduced (p < 0.05). The concentrates were lysed using freeze/thaw cycles, which eliminated the cells while growth factor concentrations were maintained. Donor age negatively correlated with platelet and growth factor concentrations after processing (p < 0.05). Finally, all lysates were pooled and the ePL was evaluated as culture medium supplement in comparison with FBS, using adipose-derived MSC from four unrelated donor horses. MSC proliferated well in 10% FBS as well as in 10% ePL. However, using 5 or 2.5% ePL entailed highly inconsistent proliferation or loss of proliferation, with significant differences in generation times and confluencies (p < 0.05). MSC expressed the surface antigens CD90, CD44, and CD29, but CD73 and CD105 detection was low in all culture media. Adipogenic and osteogenic differentiation led to similar results in MSC from different culture media. The buffy coat method is useful to produce equine platelet concentrate with increased platelet and reduced white blood cell content in large scales. The ePL obtained supports MSC expansion similar as FBS when used at the same concentration (10%). Further investigations into equine MSC functionality in culture with ePL should follow.
format Online
Article
Text
id pubmed-7859354
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78593542021-02-05 Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture Hagen, A. Lehmann, H. Aurich, S. Bauer, N. Melzer, M. Moellerberndt, J. Patané, V. Schnabel, C. L. Burk, J. Front Bioeng Biotechnol Bioengineering and Biotechnology Translation of multipotent mesenchymal stromal cell (MSC)-based therapies is advancing in human and veterinary medicine. One critical issue is the in vitro culture of MSC before clinical use. Using fetal bovine serum (FBS) as supplement to the basal medium is still the gold standard for cultivation of many cell types including equine MSC. Alternatives are being explored, with substantial success using platelet lysate-supplemented media for human MSC. However, progress lags behind in the veterinary field. The aim of this study was to establish a scalable protocol for equine platelet lysate (ePL) production and to test the ePL in equine MSC culture. Whole blood was harvested into blood collection bags from 20 healthy horses. After checking sample materials for pathogen contamination, samples from 19 animals were included. Platelet concentrates were prepared using a buffy coat method. Platelets, platelet-derived growth factor BB, and transforming growth factor β1 concentrations were increased in the concentrates compared with whole blood or serum (p < 0.05), while white blood cells were reduced (p < 0.05). The concentrates were lysed using freeze/thaw cycles, which eliminated the cells while growth factor concentrations were maintained. Donor age negatively correlated with platelet and growth factor concentrations after processing (p < 0.05). Finally, all lysates were pooled and the ePL was evaluated as culture medium supplement in comparison with FBS, using adipose-derived MSC from four unrelated donor horses. MSC proliferated well in 10% FBS as well as in 10% ePL. However, using 5 or 2.5% ePL entailed highly inconsistent proliferation or loss of proliferation, with significant differences in generation times and confluencies (p < 0.05). MSC expressed the surface antigens CD90, CD44, and CD29, but CD73 and CD105 detection was low in all culture media. Adipogenic and osteogenic differentiation led to similar results in MSC from different culture media. The buffy coat method is useful to produce equine platelet concentrate with increased platelet and reduced white blood cell content in large scales. The ePL obtained supports MSC expansion similar as FBS when used at the same concentration (10%). Further investigations into equine MSC functionality in culture with ePL should follow. Frontiers Media S.A. 2021-01-21 /pmc/articles/PMC7859354/ /pubmed/33553119 http://dx.doi.org/10.3389/fbioe.2020.613621 Text en Copyright © 2021 Hagen, Lehmann, Aurich, Bauer, Melzer, Moellerberndt, Patané, Schnabel and Burk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Hagen, A.
Lehmann, H.
Aurich, S.
Bauer, N.
Melzer, M.
Moellerberndt, J.
Patané, V.
Schnabel, C. L.
Burk, J.
Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title_full Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title_fullStr Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title_full_unstemmed Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title_short Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture
title_sort scalable production of equine platelet lysate for multipotent mesenchymal stromal cell culture
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859354/
https://www.ncbi.nlm.nih.gov/pubmed/33553119
http://dx.doi.org/10.3389/fbioe.2020.613621
work_keys_str_mv AT hagena scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT lehmannh scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT aurichs scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT bauern scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT melzerm scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT moellerberndtj scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT patanev scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT schnabelcl scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture
AT burkj scalableproductionofequineplateletlysateformultipotentmesenchymalstromalcellculture